IDORSIA AG SF-,05
0,768€
-0,057 (-6,97%)
24.01.2025, 22:58:10 Uhr
WKN: A2DTEB ISIN: CH0363463438 Wertpapiertyp: Aktie Währung: Euro
- 1T
- 1W
- 1M
- 3M
- 6M
- 1J
- 3J
- 5J
- 10J
- Max
Weltmärkte
- DAX ® -16,60 -0,08% 21.394,93
- MDAX ® +157,22 +0,61% 26.108,46
- TecDAX ® -8,82 -0,24% 3.648,19
- E-STOXX 50 ® +1,87 +0,04% 5.219,37
- NASDAQ 100 -126,92 -0,58% 21.774,01
- HANG SENG +336,76 +1,71% 20.066,19
Kursperformance
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Tag | 0,768€ | -6,97% |
| 1 Woche | 0,850€ | -9,65% |
| 1 Monat | 0,781€ | -1,66% |
| 6 Monate | 2,462€ | -68,81% |
| Lfd. Jahr (YTD) | 0,872€ | -11,98% |
| 1 Jahr | 1,446€ | -46,89% |
| 3 Jahre | 19,718€ | -96,11% |
| 5 Jahre | 31,488€ | -97,56% |
Kursdaten
| Kurs | 0,768€ |
| Eröffnung | 0,829€ |
| Geld | 0,757€ |
| Brief | 0,786€ |
| Tages-Hoch | 0,829€ |
| Tages-Tief | 0,768€ |
| 52 Wochen-Hoch | 3,524€ |
| 52 Wochen-Tief | 0,448€ |
| Allzeit-Hoch | 31,650€ |
| Allzeit-Tief | 0,448€ |
Nachrichten
- GlobeNewswire: New data with daridorexant to be presented at SLEEP 2024 - 03.06.2024, 07:00:00 Uhr
- GlobeNewswire: Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024 - 31.05.2024, 07:00:00 Uhr
- GlobeNewswire: Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders - 23.05.2024, 07:00:00 Uhr
- GlobeNewswire: Idorsia announces changes to Idorsia Executive Committee and Board of Directors - 21.05.2024, 07:00:00 Uhr
- GlobeNewswire: Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor - 21.05.2024, 06:50:00 Uhr
- GlobeNewswire: Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value - 21.05.2024, 06:40:00 Uhr
- GlobeNewswire: Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call - 14.05.2024, 17:45:00 Uhr
- GlobeNewswire: Bondholders approve amended terms of the 2024 convertible bonds - 06.05.2024, 18:35:00 Uhr
- GlobeNewswire: Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond - 01.05.2024, 18:00:00 Uhr
- GlobeNewswire: JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension - 26.04.2024, 07:00:00 Uhr
